Photo by diabetesmagazijn from unsplash
DWP16001, a novel sodium–glucose cotransporter 2 inhibitor, is under clinical development for the treatment of type 2 diabetes mellitus. This study aimed to explore the pharmacokinetics (PK) and pharmacodynamics interaction… Click to show full abstract
DWP16001, a novel sodium–glucose cotransporter 2 inhibitor, is under clinical development for the treatment of type 2 diabetes mellitus. This study aimed to explore the pharmacokinetics (PK) and pharmacodynamics interaction of DWP16001 with gemigliptin and metformin.
Keywords:
cotransporter inhibitor;
glucose cotransporter;
gemigliptin metformin;
dwp16001;
interaction dwp16001;
sodium glucose
Journal Title: British Journal of Clinical Pharmacology
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: British Journal of Clinical Pharmacology
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!